[(2R)-4,4-二氟吡咯烷-2-基]甲醇盐酸盐 | 1315593-71-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: [(2R)-4,4-二氟吡咯烷-2-基]甲醇盐酸盐
• 英文名称: (R)-(4,4-difluoropyrrolidin-2-yl)methanol hydrochloride
• 英文别名: [(2R)-4,4-difluoropyrrolidin-2-yl]methanol;hydrochloride
• CAS: 1315593-71-5
• 化学式: C₅H₉F₂NO*ClH
• 分子量: 173.59
• InChiKey: JWAVXSQHRZARDV-PGMHMLKASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [(2R)-4,4-二氟吡咯烷-2-基]甲醇盐酸盐 、 在 溶剂黄146 、 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 以91 g的产率得到ethyl cis-2-{4-[(2R)-4,4-difluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate
  参考文献：
  名称：

  [EN] MUSCARINIC RECEPTOR AGONISTS
  [FR] AGONISTES DU RÉCEPTEUR MUSCARINIQUE

  摘要：

  This invention relates to compounds and salts thereof that are muscarinic receptor agonists and which are useful in the treatment of muscarinic receptor mediated diseases. Also provided are crystalline forms of the compounds and salts thereof; pharmaceutical compositions containing the compounds and salts thereof, or crystalline forms thereof; therapeutic uses of the compounds and salts thereof, or crystalline forms thereof; methods of synthesis thereof; and intermediates useful in said methods of synthesis.

  公开号：

  WO2024028458A2
• 作为产物：
  描述：

  2-甲基(2R)-4,4-二氟吡咯烷-1,2-二羧酸1-叔丁基酯 在 盐酸 、 锂硼氢 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 19.83h， 生成 [(2R)-4,4-二氟吡咯烷-2-基]甲醇盐酸盐
  参考文献：
  名称：

  [EN] MUSCARINIC RECEPTOR AGONISTS
  [FR] AGONISTES DU RÉCEPTEUR MUSCARINIQUE

  摘要：

  This invention relates to compounds and salts thereof that are muscarinic receptor agonists and which are useful in the treatment of muscarinic receptor mediated diseases. Also provided are crystalline forms of the compounds and salts thereof; pharmaceutical compositions containing the compounds and salts thereof, or crystalline forms thereof; therapeutic uses of the compounds and salts thereof, or crystalline forms thereof; methods of synthesis thereof; and intermediates useful in said methods of synthesis.

  公开号：

  WO2024028458A2

文献信息

• NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130116236A1

  公开（公告）日：2013-05-09

  The invention relates to a compound of formula (I) wherein A, R 1 and R 2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

  该发明涉及一种化合物，其化学式为（I），其中A，R1和R2的定义如描述和索赔中所述。化合物的化学式（I）可用作药物。
• [EN] [1, 2, 3] TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2<br/>[FR] DERIVES DE [1,2,3]]TRIAZOLO[4,5-D]PYRIMIDINE COMME AGONISTES DU RECEPTEUR CANNABINOIDE 2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013068306A1

  公开（公告）日：2013-05-16

  The invention relates to a compound of formula (I), wherein A, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament as agonists of the cannabinoid receptor 2.

  该发明涉及一种化合物，其化学式为(I)，其中A、R1和R2的定义如描述和权利要求中所述。化合物的化学式(I)可用作大麻素受体2的激动剂药物。
• [1,2,3]triazolo[4,5-D]pyrimidine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US08741906B2

  公开（公告）日：2014-06-03

  The invention relates to a compound of formula (I) wherein A, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

  本发明涉及一种化合物，其化学式为（I），其中A、R1和R2如说明书和权利要求书中所定义。该化合物可用作药物。
• Sulfonamide compounds
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US11046710B2

  公开（公告）日：2021-06-29

  The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.

  本发明涉及一种具有优异的组织非特异性碱性磷酸酶抑制活性的化合物或其药理学上可接受的盐。本发明提供了一种由式（I）代表的化合物或其药理学上可接受的盐。
• [1, 2, 3]TRIAZOLO [4, 5 -D]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2776442B1

  公开（公告）日：2015-10-21